NCT07328217招募中1 期
A Phase 1/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Efficacy of GW5282 in Participants With Advanced Solid Tumors (BEI-DOU2)
Dizal Pharmaceuticals3 个研究点 分布在 1 个国家目标入组 203 人开始时间: 2026年1月29日最近更新:
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 203
- 试验地点
- 3
- 主要终点
- Incidence of Dose Limiting Toxicities (DLTs) (Dose Escalation only)
研究概览
简要总结
This is a phase 1/2, open-label, multicenter study assessing the safety, tolerability, pharmacokinetics and efficacy of GW5282 in participants with locally advanced or metastatic solid tumors. This study comprised of a dose escalation phase to determine the MTD and the RP2D and a dose expansion phase to further explore the safety, PK and efficacy of GW5282.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All participants must provide a signed, dated written informed consent (ICF) prior to any study-specific procedures, sampling, and analysis.
- •Male and female participants must be ≥18 years of age at the time of signing the ICF.
- •Eastern Cooperative Oncology Group performance status of 0-
- •Histologically or cytologically confirmed locally advanced or metastatic solid tumors who has failed standard of cares (SoCs).
- •Life expectancy ≥3 months.
- •At least one measurable lesion according to RECIST 1.
- •Tumor tissue sample requirements: sections of formalin-fixed paraffin-embedded (FFPE) tissue from freshly obtained biopsy sample or archived tumor sample.
- •Adequate organ and marrow function.
- •Participants should be able to comply with the requirements of this study for medication use and follow-up.
- •If the female partner of a male participant has a potential for pregnancy, he must agree to use contraception (such as condoms) and refrain from donating sperm during the treatment period and for at least 6 months after the last dose of study treatment.
- •Female participants should use adequate contraception during the treatment period and for at least 3 months after the last dose of study treatment. Female participants with potential pregnancy should have a negative pregnancy test prior to the first administration of investigational drug. Female participants may also be enrolled if they meet one of the following criteria:
- •Postmenopausal women: older than 50 years and more than 12 months postmenopausal after discontinuation of all exogenous hormone therapy. Women under 50 years of age, more than 12 months postmenopausal after discontinuation of all exogenous hormone therapy, and with luteinizing hormone and follicle-stimulating hormone levels at postmenopausal levels.
- •History of irreversible hysterectomy, bilateral oophorectomy, or bilateral salpingectomy (excluding tubal ligation)."
排除标准
- •Any unresolved > grade 1 (according to CTCAE version 5.0) adverse event (excluding alopecia, anemia, neutropenia, and thrombocytopenia) prior to the first administration of investigational drug.
- •Any known active central nervous system metastases and/or carcinomatous meningitis and/or spinal cord compression.
- •Having any of the following treatment history:
- •previously treated with GW5282 or other EZH pathway inhibitors.
- •previously received any cytotoxic chemotherapy, investigational drug, or other anticancer drug (excluding macromolecular drugs) or clinical trial within 7 days or 5 half-lives (whichever is longer) prior to the first administration of the investigational drug.
- •previously received any macromolecular drug (such as immunotherapy, monoclonal antibodies, bispecific antibodies, or antibody-drug conjugates) within 28 days prior to the first administration of the investigational drug.
- •Underwent major surgery (excluding vascular access surgery) or suffered severe trauma within 4 weeks prior to the first administration of the investigational drug.
- •Received limited field of radiation to alleviate symptoms within 7 days prior to the first administration of the investigational drug, or received more than 30% or extensive field of radiation to the bone marrow within 28 days prior to the first administration of the investigational drug.
- •Received live-attenuated vaccine or viral vector vaccine within 4 weeks prior to the first administration of the investigational drug."
- •Active infectious diseases.
- •History of stroke or intracranial hemorrhage within 6 months prior to the first administration of the investigational drug.
- •History of interstitial lung disease (ILD), radiation pneumonitis requiring corticosteroid therapy, or any clinically active interstitial lung disease, or immunotherapy-related pneumonitis.
- •Uncontrolled systemic disease including uncontrolled hypertension and active bleeding after investigator's assessment.
- •Judgment by the investigator that the participant is unlikely to comply with the study procedures, restrictions, and requirements.
研究组 & 干预措施
Dose Escalation Phase
Experimental
Escalating doses of GW5282 administered orally
干预措施: GW5282 (Drug)
Dose Expansion phase
Experimental
The recommended dose(s) for expansion (RDFE) for GW5282 from dose escalation phase will be evaluated in selected tumors.
干预措施: GW5282 (Drug)
结局指标
主要结局
Incidence of Dose Limiting Toxicities (DLTs) (Dose Escalation only)
时间窗: Up to 21 days
Number of participants with Adverse Events (AEs)
时间窗: Approximately 24 months from first participant enrolled
Number of Participants with Serious Adverse Events (SAEs)
时间窗: Approximately 24 months from first participant enrolled
Overall Response Rate (ORR)
时间窗: Approximately 24 months from first participant enrolled
ORR is defined as the percentage of subjects with Best Response of Complete Response (CR) or Partial Response (PR) as determined by the investigator
次要结局
- Cmax; Maximum Plasma Concentration of GW5282(Single dose period (only for dose escalation phase): 0 (predose) up to 72 hours post-dose)
- AUCss; Area Under the Plasma Concentration-time Curve Over the Dosing Interval at Steady State of GW5282(Cycle 1 Day 15: 0 (predose) up to 12 hours post-dose)
- AUC; Area Under the Plasma Concentration-time Curve of GW5282(Single dose period (only for dose escalation phase): 0 (predose) up to 72 hours post-dose)
- Tmax; Time to Reach Maximum Plasma Concentration (Cmax) of GW5282(Single dose period (only for dose escalation phase): 0 (predose) up to 72 hours post-dose)
- Css,max; Maximum Steady State Plasma Concentration of GW5282(Cycle 1 Day 15: 0 (predose) up to 12 hours post-dose)
- Duration of response (DOR)(Approximately 24 months from first participant enrolled)
- Tss,max; Time to Reach Maximum Plasma Concentration (Cmax) at Steady State of GW5282(Cycle 1 Day 15: 0 (predose) up to 12 hours post-dose)
- Disease Control Rate (DCR)(Approximately 24 months from first participant enrolled)
- Progression-free survival (PFS)(Approximately 24 months from first participant enrolled)
研究者
研究点 (3)
Loading locations...
相似试验
招募中
1 期
A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid TumorNCT07275242Suzhou Suncadia Biopharmaceuticals Co., Ltd.107
招募中
2 期
A Trial to Determine The Safety and Efficacy of CC-92480 Alone and When Combined With Dexamethasone in People Who Have Myeloma That is Not Responsive After Treatment or Who Had Myeloma Which Has Returned After a Period of Treatment2023-508727-12-00Celgene Corp.46
尚未招募
2 期
A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung CancerNCT07283198Jiangsu Alphamab Biopharmaceuticals Co., Ltd160
招募中
1 期
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid TumorsColorectal CancerNon-Small Cell Lung CancerNCT07261631Novartis Pharmaceuticals180
招募中
1 期
A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid TumorsNCT07265921Jiangsu Simcere Pharmaceutical Co., Ltd.232